Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM1021 Monotherapy and Combination with PM8001 in Advanced Solid Tumors
NCT05537051Phase 1Not yet recruiting
- Sponsor
- Biotheus
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of PM1021 in solid tumor (advanced stage) (2 arms), sponsored by Biotheus. Primary endpoints: Dose-Limiting Toxicity up to 21 days and Adverse Events. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
PM1021
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05537051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537051.